Who founded Kalaris Therapeutics, Inc.?

Kalaris Therapeutics, Inc. was founded by Srinivas Akkaraju, Mike Dybbs, Napoleone Ferrara.

Who are Kalaris Therapeutics, Inc.'s investors?

Kalaris Therapeutics, Inc.'s investors include Samsara BioCapital, Invus, RTW Investments L.P..

Where is Kalaris Therapeutics, Inc. headquartered?

Kalaris Therapeutics, Inc. is headquartered in Berkeley Heights, US.

Kalaris Therapeutics, Inc.

NASDAQ: KLRSUnicorn · $1.1B

Berkeley Heights, US · 3 known investors

Find your way into Kalaris Therapeutics, Inc.

769 people in our graph share verified history with the Kalaris Therapeutics, Inc. team — schools, employers, funds. One of them is your warm intro.

Adam Valkinunlockedknows Mike Dybbs · together at Harvard University (overlapped)

×7knows the team · via University of California, Berkeley

×4knows the team · via Harvard University

Kalaris Therapeutics is a clinical-stage biopharmaceutical company developing treatments for prevalent retinal diseases such as wet AMD, diabetic eye disease, and retinal vein occlusion. Its lead asset is an engineered dual-targeting biologic aimed at longer-lasting anti-VEGF activity to reduce the frequency of injections for patients.

Biotech Healthtech

Founders & leadership

Srinivas AkkarajuDirector & Co-founderGeneral Partner at Samsara BioCapital

Mike Dybbs in 𝕏Director & Co-founderPartner at Samsara BioCapital

Napoleone FerraraDirector & Co-Founder

Andrew OxtobyinCEO & Director

Matthew FeinsodCMO

Liisa BaykoCFO

Investors · 3

Samsara BioCapitalPalo Alto

InvusreportedNew York

RTW Investments L.P.reportedNew York

Funding

SEC filings, press & company announcements

Undisclosed amountprivate placementDec 2025
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Valuation · disclosed

Disclosed events

$1.1Bvaluation at IPOJul 2020 · $17.00/share · 424B4

filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

In the news

Why Kalaris Therapeutics, Inc.’s (KLRS) Stock Is Up 5.69% | AAIIaaii.com · May 2026

Kalaris Therapeutics Reports Q1 2026 Financial Results and Advances TH103 Clinical Trials for Retinal Diseases – Minichartminichart.com.sg · May 2026

WilmerHale Advises Kalaris Therapeutics on $50 Million Private Placementwilmerhale.com · Dec 2025

Kalaris Therapeutics raises $50M via private placement financing | KLRS SEC Filing - Form 8-Kstocktitan.net · Dec 2025

Kalaris Therapeutics, Inc. announced that it expects to receive $49.99992 million in funding | MarketScreenermarketscreener.com · Dec 2025

Frequently asked questions

What does Kalaris Therapeutics, Inc. do?: Kalaris Therapeutics is a clinical-stage biopharmaceutical company developing treatments for prevalent retinal diseases such as wet AMD, diabetic eye disease, and retinal vein occlusion. Its lead asset is an engineered dual-targeting biologic aimed at longer-lasting anti-VEGF activity to reduce the frequency of injections for patients.
Who founded Kalaris Therapeutics, Inc.?: Kalaris Therapeutics, Inc. was founded by Srinivas Akkaraju, Mike Dybbs, Napoleone Ferrara.
Who are Kalaris Therapeutics, Inc.'s investors?: Kalaris Therapeutics, Inc.'s investors include Samsara BioCapital, Invus, RTW Investments L.P..
Where is Kalaris Therapeutics, Inc. headquartered?: Kalaris Therapeutics, Inc. is headquartered in Berkeley Heights, US.